Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Metagenomi, Inc. stock logo
MGX
Metagenomi
$1.15
$1.19
$1.07
▼
$3.95
$43.44M0.67153,198 shs70,755 shs
Moderna, Inc. stock logo
MRNA
Moderna
$198.88
+2.1%		$111.78
$22.28
▼
$202.67
$79.40B1.115.21 million shs13.90 million shs
NGEN
NervGen Pharma
$1.94
-4.0%		$1.93
$1.58
▼
$6.30
$156.42MN/A537,498 shs343,193 shs
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$0.64
-2.4%		$0.83
$0.16
▼
$2.54
$155.69M0.744.28 million shs2.93 million shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Metagenomi, Inc. stock logo
MGX
Metagenomi
0.00%+4.55%-4.96%-8.00%-44.98%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%+29.12%+39.30%+195.64%+668.47%
NGEN
NervGen Pharma
0.00%-5.37%-17.09%+3.74%+193,999,900.00%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
0.00%-1.93%-0.17%-62.57%-35.26%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Metagenomi, Inc. stock logo
MGX
Metagenomi
$1.15
$1.19
$1.07
▼
$3.95
$43.44M0.67153,198 shs70,755 shs
Moderna, Inc. stock logo
MRNA
Moderna
$198.88
+2.1%		$111.78
$22.28
▼
$202.67
$79.40B1.115.21 million shs13.90 million shs
NGEN
NervGen Pharma
$1.94
-4.0%		$1.93
$1.58
▼
$6.30
$156.42MN/A537,498 shs343,193 shs
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$0.64
-2.4%		$0.83
$0.16
▼
$2.54
$155.69M0.744.28 million shs2.93 million shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Metagenomi, Inc. stock logo
MGX
Metagenomi
0.00%+4.55%-4.96%-8.00%-44.98%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%+29.12%+39.30%+195.64%+668.47%
NGEN
NervGen Pharma
0.00%-5.37%-17.09%+3.74%+193,999,900.00%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
0.00%-1.93%-0.17%-62.57%-35.26%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Metagenomi, Inc. stock logo
MGX
Metagenomi
2.75
Moderate Buy$6.00421.74% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.13
Hold$76.72-61.42% Downside
NGEN
NervGen Pharma
2.83
Moderate Buy$14.00621.65% Upside
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2.20
Hold$5.20712.50% Upside

Current Analyst Ratings Breakdown

Latest MGX, MRNA, OTLK, and NGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/25/2026
Moderna, Inc. stock logo
MRNA
Moderna
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
9/22/2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
9/22/2026
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/9/2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
9/9/2026
Moderna, Inc. stock logo
MRNA
Moderna
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$81.00
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Sell
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
Rothschild & Co Redburn logo
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeNeutral ➝ Sell$40.00 ➝ $81.00
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
CLSA logo
CLSA
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform
(Data available from 9/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Metagenomi, Inc. stock logo
MGX
Metagenomi
$13.56M3.20N/AN/A$4.22 per share0.27
Moderna, Inc. stock logo
MRNA
Moderna
$2.21B35.93N/AN/A$22.14 per share8.98
NGEN
NervGen Pharma
N/AN/AN/AN/A$0.03 per shareN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$1.16M-133.91N/AN/A($0.60) per share-1.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Metagenomi, Inc. stock logo
MGX
Metagenomi
-$87.87M-$2.49N/AN/AN/A-384.61%-63.65%-44.52%11/10/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.99N/AN/AN/A-141.43%-28.30%-19.39%11/5/2026 (Estimated)
NGEN
NervGen Pharma
-$31.58M-$0.46N/AN/AN/AN/A-1,259.82%-199.79%N/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$62.42M-$0.77N/AN/AN/AN/AN/A-254.82%N/A

Latest MGX, MRNA, OTLK, and NGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q3 2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$0.08-$0.09-$0.01-$0.15$0.97 million$0.01 million
8/13/2026Q2 2026
NGEN
NervGen Pharma
-$0.09-$0.37-$0.28-$0.37N/AN/A
8/10/2026Q2 2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
-$0.5531-$0.73-$0.1769-$0.73$3.01 million($0.26) million
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.03-$1.97+$0.06-$1.97$102.93 million$145.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
NGEN
NervGen Pharma
N/AN/AN/AN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/A
4.50
4.50
Moderna, Inc. stock logo
MRNA
Moderna
0.09
2.29
2.18
NGEN
NervGen Pharma
N/A
1.23
1.23
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/A
0.81
0.63

Institutional Ownership

CompanyInstitutional Ownership
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/A
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
NGEN
NervGen Pharma
N/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
11.20%

Insider Ownership

CompanyInsider Ownership
Metagenomi, Inc. stock logo
MGX
Metagenomi
12.50%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
NGEN
NervGen Pharma
5.80%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
1.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Metagenomi, Inc. stock logo
MGX
Metagenomi
11337.78 million33.06 millionN/A
Moderna, Inc. stock logo
MRNA
Moderna
4,700399.24 million356.12 millionOptionable
NGEN
NervGen Pharma
880.63 million75.95 millionN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
17243.45 million239.07 millionOptionable

Recent News About These Companies

Oncobiologics, Inc. (NASDAQ:OTLK) Short Interest Update
September 19, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31032622
FY2026 EPS Forecast for Oncobiologics Lifted by Analyst
September 19, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31031626
Oncobiologics (NASDAQ:OTLK) and Synlogic (NASDAQ:SYBX) Critical Comparison
September 18, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31031210
Oncobiologics, Inc. (NASDAQ:OTLK) Short Interest Up 65.4% in August
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-oncobiologics-inc-nasdaq-otlk-short-interest-up-654-in-august-2026-09-17/
Brokers Offer Predictions for Oncobiologics FY2026 Earnings
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-brokers-offer-predictions-for-oncobiologics-fy2026-earnings-2026-09-17/
Oncobiologics (NASDAQ:OTLK) Price Target Raised to $10.50 at Ascendiant Capital Markets
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-oncobiologics-nasdaq-otlk-price-target-raised-to-1050-at-ascendiant-capital-markets-2026-09-11/
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
September 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/11/3360236/0/en/outlook-therapeutics-fireside-chat-from-h-c-wainwright-conference-now-available-on-demand.html
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
September 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/10/3359613/0/en/outlook-therapeutics-ceo-bob-jahr-discusses-fda-approval-and-commercial-opportunity-for-lytenava-in-virtual-investor-ceo-connect-segment.html
Oncobiologics, Inc. (NASDAQ:OTLK) Receives Consensus Recommendation of "Hold" from Analysts
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-oncobiologics-inc-nasdaq-otlk-receives-consensus-recommendation-of-hold-from-analysts-2026-09-09/
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
August 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/27/3352397/0/en/outlook-therapeutics-appoints-kevin-lundquist-as-chief-financial-officer-as-it-prepares-for-u-s-commercial-launch-of-lytenava.html
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
August 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/27/3352076/0/en/outlook-therapeutics-ceo-bob-jahr-participates-in-the-virtual-investor-why-now-on-demand-conference.html
OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp
August 17, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2975675/otlk-q3-earnings-call-maps-lytenava-u-s-launch-and-sales-ramp?cid=cs-stocknewsapi-ft-analyst_blog_plus|earnings_call_takeaways-2975675
Contrasting Oncobiologics (NASDAQ:OTLK) & enGene (NASDAQ:ENGN)
August 15, 2026  |  defenseworld.netD
Insider Buying: Oncobiologics (NASDAQ:OTLK) Director Acquires $2,499,999.48 in Stock
August 15, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-otlk-insider-buying-and-selling-2026-08-15/
Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript
August 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4936801-outlook-therapeutics-inc-otlk-q3-2026-earnings-call-transcript
Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
August 14, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2974790/outlook-therapeutics-inc-otlk-reports-q3-loss-lags-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2974790
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
August 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/14/3345250/0/en/outlook-therapeutics-reports-third-quarter-fiscal-year-2026-financial-results-and-provides-business-update-highlighting-fda-approval-of-lytenava.html
Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
August 14, 2026  |  benzinga.comhttps://www.benzinga.com/analyst-stock-ratings/price-target/26/08/61200760/outlook-therapeutics-gears-up-for-q3-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts?utm_source=snapi
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
August 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344189/0/en/outlook-therapeutics-announces-pricing-of-55-0-million-public-offering-of-common-stock-and-warrants.html
OTLK Up More Than 300% in 3 Months: Here's What You Should Know
August 10, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2972032/otlk-up-more-than-300-in-3-months-here-s-what-you-should-know?cid=cs-stocknewsapi-ft-analyst_blog|price_surge_/_plunge-2972032
Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
August 6, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2970019/outlook-therapeutics-inc-otlk-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q3-release?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_9-2970019

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
Gold-colored concept electric vehicle with a smooth, minimalist body parked outdoors near a building and tree.
Ride-Share Reckoning: Tesla Drives Into Uber's Lane
By Jeffrey Neal Johnson | September 7, 2026
Scientist handles blood sample in lab, symbolizing early cancer detection.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
By Bridget Bennett | September 6, 2026
Metagenomi stock logo

Metagenomi NASDAQ:MGX

$1.15 0.00 (0.00%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$1.15 0.00 (-0.09%)
As of 09/25/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Moderna stock logo

Moderna NASDAQ:MRNA

$198.88 +4.06 (+2.08%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$197.82 -1.06 (-0.53%)
As of 09/25/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

NervGen Pharma NASDAQ:NGEN

$1.94 -0.08 (-3.96%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$1.98 +0.04 (+2.06%)
As of 09/25/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.

Oncobiologics stock logo

Oncobiologics NASDAQ:OTLK

$0.64 -0.02 (-2.41%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$0.65 +0.01 (+1.09%)
As of 09/25/2026 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas